This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does TransMedics (TMDX) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for TransMedics (TMDX) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Hold IART Stock in Your Portfolio Now
by Zacks Equity Research
Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
Best Momentum Stocks to Buy for October 3rd
by Zacks Equity Research
TMDX, CCL, and CBU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2024.
Is it the Right Time to Hold EW Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
by Zacks Equity Research
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
New Strong Buy Stocks for October 3rd
by Zacks Equity Research
CCL, TMDX, CBU, RWEOY and ADDYY have been added to the Zacks Rank #1 (Strong Buy) List on October 3, 2024.
HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?
by Zacks Equity Research
Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.
Here's Why You Should Add BSX Stock to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
Global Expansion, Strategic Innovations Aid Boston Scientific Stock
by Zacks Equity Research
We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan
by Zacks Equity Research
Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.
TransMedics (TMDX) Moves 10.1% Higher: Will This Strength Last?
by Zacks Equity Research
TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
HOLX Stock Gains From New Offerings Despite Macro Issues
by Zacks Equity Research
In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.
VRNOF Stock Likely to Gain From Its Newly Opened Dispensary in Phoenix
by Zacks Equity Research
Verano is set to open a new Zen Leaf Arcadia in Phoenix, AZ, today. Zen Leaf Arcadia is located at 2710 E Indian School Road, Phoenix. It will be open daily from 8 a.m. to 10 p.m. local time.
Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock
by Zacks Equity Research
Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
Here's Why You Should Add HAE Stock in Your Portfolio Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
by Zacks Equity Research
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
Should You Continue to Retain LH Stock in Your Portfolio?
by Zacks Equity Research
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.